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quarterly per-prescription reimbursements were deﬁned as total reimbursement 
amounts divided by total prescriptions. The market shares were calculated based on 
the proportion of total prescription numbers. RESULTS: The total reimbursement for 
AMDs increased from $1.6 million in 1991 to $156 million in 2004, and dropped to 
$115 million in 2008. Prescriptions for AMDs increased from 56,410 in 1991 to 
948,597 in 2004, and then dropped to 542,093 in 2008. The ergot prescriptions 
increased from 25,540 in 1991 to 47,543 in 1995, then gradually decreased to 6,367 
in 2008. A similar utilization trend was found for ergot combination products. Mean-
while, triptan prescriptions increased from 23,523 in 1995 to 912,978 in 2004, and 
dropped to 524,922 in 2008. The market share for triptans increased dramatically 
from 0% in 1994 to 97% in 2008, while the market share for ergot derivatives and 
ergot combination products decreased from 45% and 55% in 1991 to 1% and 2% 
in 2008, respectively. The per-prescription cost of branded triptans has steadily 
increased since 1994, regardless of newer brand entries. CONCLUSIONS: Triptan use 
has increased dramatically and dominated the AMD market. However, triptan utiliza-
tion dropped 34.91% in 2006. This may be due to the implementation of Medicare 
Part D.
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OBJECTIVES: Antiepileptic drugs (AEDs) are one of the most frequently prescribed 
medication classes in U.S. The objectives of this study were to describe AED utiliza-
tion, price and reimbursement trends and to analyze the market share competition 
between traditional and newer AEDs. METHODS: A retrospective, descriptive time-
series analysis was performed using the National Medicaid pharmacy claims database 
from 1991 to 2008. Quarterly number of prescriptions and reimbursement data 
were calculated for the trends analysis. Study drugs included all brand and generic 
names of newer AEDs (e.g., gabapentin, lamotrigine, topiramate, fosphenytoin) and 
traditional AEDs (e.g., tiagabine, valproate, zonisamide, carbamzepine). Market share 
for AEDs was quantiﬁed annually. The quarterly price per prescription was calculated 
by dividing the total reimbursement by the total number of prescriptions. RESULTS: 
The total number of newer AED prescriptions increased from 32,837 prescriptions 
totaling $2.2 million reimbursement in 1993 to 7.7 million totaling $1.2 billion in 
2005, and dropped to 4.3 million totaling $847 million in 2008. Meanwhile, tra-
ditional AED prescriptions increased from 5.14 million totaling $154 million reim-
bursement in 1991 to 20.5 million totaling $1.22 billion in 2004, and dropped to 
11.5 million totaling $447 million in 2008. The average annual increase in number 
of prescriptions was 71.3% for newer and 6.95% for traditional AEDs. The market 
share of newer AED prescriptions increased from 1% in 1993 to 28% in 2005, and 
27% in 2008. Fosphenytoin remained the most expensive newer AED with price of 
$211 in 1996 and $391 in 2005. Valproic acid and clorazepate were the most 
expensive traditional AEDs, with prices varying from $150 to $600. CONCLU-
SIONS: There has been substantial increase in use of AED, which may be due to 
off-label use, new indications, and as adjunct therapy. A signiﬁcant drop in AED 
utilization trends since 2004 may potentially be due to Medicare part D introduction 
and patent expiration.
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OBJECTIVES: Multiple sclerosis (MS) is a chronic illness leading to permanent dis-
ability. As the disease progresses, MS patients may require home personal care (HPC). 
HPC assists patients with activities of daily living (ADLs) and homemaking, so patients 
can continue living in their homes. This study examines the extent as well as the bar-
riers and facilitators of HPC use by MS patients. METHODS: We analyzed data for 
1577 participants in the 2000–2005 Sonya Slifka survey of MS patients. This survey 
provides information on disease status, socio-demographics, family information, and 
HPC use. We constructed 3 outcome measures: use of paid HPC, use of help with 
ADLs or instrumental ADLs (IADLs), and unmet need. Logistic regression with sam-
pling weights and robust standard errors were employed to examine the association 
between each outcome and patient characteristics. RESULTS: Greater disability was 
associated with greater use of paid HPC (P < 0.001) and greater assistance received 
for ADLs/ IADLS (P < 0.001). Patients on Medicaid used more paid HPC (OR = 1.74, 
p = 0.01) and had less unmet need (OR = 0.53, p = 0.03). Medicare beneﬁciaries 
received more assistance with ADLs/IADLs (OR = 1.42, p = 0.02), but did not receive 
more paid care. Patients living with a spouse/partner purchased fewer services (OR = 
0.64, p = 0.01), while receiving more help overall with functional limitations or chores 
(OR = 2.06, p < 0.01). Patients with greater family income reported lower unmet need 
(OR = 0.36, p < 0.01). CONCLUSIONS: Type of insurance and marital status are 
important predictors of HPC use among the MS population. While patients who live 
with a spouse/partner often have higher family income and can afford more paid HPC, 
they appear to delegate the more burdensome ADL care to their family, while being 
more inclined to pay for help with homemaking. Overall, these patients had lower 
unmet needs and used less paid help than patients living alone.
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OBJECTIVES: Alzheimer’s disease is the sixth-leading cause of death in the United 
States. The health and economic costs associated with the disease are enormous. 
We forecast and quantify this burden until year 2050 and evaluate the potential 
impacts of delayed onset of Alzheimer’s disease. METHODS: We use a dynamic 
micro-simulation model to predict health status (Alzheimer’s disease as one of the 
measures) and economic situations of Americans 50 years and older, from year 2004 
to 2050. To estimate the burden of Alzheimer’s disease, we estimate a scenario in 
which there is no incidence of Alzheimer’s disease and compare outcomes with 
projections of the status-quo over future years. To evaluate the impacts of potential 
treatments to delay the onset of Alzheimer’s disease, we run three scenarios in which 
there is 2-year, 4-year, or 6-year delay of onset of Alzheimer’s disease. The main 
data sources are the Health and Retirement Study and the Aging, Demographics, 
and Memory Study. The health outcome measured is Quality-Adjusted Life Years. 
Economic outcomes include earnings and tax revenues, health care costs and long-
term care costs (total, Medicare, Medicaid), opportunity costs for unpaid caregivers, 
and Social Security outlays. RESULTS: The population with Alzheimer’s disease will 
increase by more than 150 percent in year 2050. Relative to the status-quo, eliminat-
ing Alzheimer’s disease would raise tax revenues, and reduce cumulative Medicare 
costs. Alternatively, cumulative Medicaid spending and Social Security beneﬁts would 
increase, outweighing the savings in Medicare spending and raised tax revenues. We 
will also present the gains in QALYs and savings in unpaid care-giving under dif-
ferent intervention scenarios. CONCLUSIONS: Preventing Alzheimer’s disease will 
increase life expectancy and quality of life. However, these health beneﬁts will 
increase government spending as increased longevity results in longer outlays of 
annuities and health spending.
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OBJECTIVES: Insomnia is the most common sleep complaint worldwide. Our study 
aims to identify physician and patient characteristics likely to inﬂuence insomnia 
prescription patterns. METHODS: The project utilized data from National Ambula-
tory Medical Care Survey, conducted by the US. Department of Health and Human 
Services. The study subjects were selected from 2006 outpatient visits in which at 
least one frequently used insomnia medication was prescribed. A series of population-
based descriptive analyses were used to estimate the national weighted frequencies 
of selected insomnia drug prescriptions. We further constructed a weighted logistic 
regression model to estimate the odds ratio and marginal probabilities of covariates 
toward predicting insomnia drug prescriptions. RESULTS: Among the 901.8 million 
outpatient visits that took place in the US in 2006, an estimated 21.07 million visits 
included at least one insomnia drug prescription. The results from a multivariate 
logistic regression showed that a patient’s race and age, physician’s clinic ownership, 
type of ofﬁce setting, and employment status were signiﬁcantly associated with 
insomnia drug prescriptions. Black patients were 2.4 times more likely to receive 
insomnia prescription than were white patients (OR = 2.4; 95% Wald CI (1.26–
4.69)). Older patients were more likely received insomnia prescription than were 
younger patients. Patients with 3–5 visits over the course of 12 months received 
fewer insomnia prescription than did patients with only 1 visit (OR = 0.44; 95% 
Wald CI (0.21–0.93)). Physicians who worked in the academic health center pre-
scribed fewer insomnia drugs than did physicians who worked in the private practices 
(OR = 0.29; 95% Wald CI (0.09–0.91)). Employed or contracted physicians pre-
scribed a signiﬁcantly higher number of insomnia drugs than did owner physicians 
(OR = 3.6; 95% Wald CI (1.87–6.78)). CONCLUSIONS: Our ﬁndings indicate 
various sociodemographic disparities in the use of insomnia prescriptions. The study 
also demonstrated a comprehensive analytical framework, which is especially appli-
cable to population-based data mining research.
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OBJECTIVES: To evaluate the agreement between data derived from medical charts 
of patients with multiple sclerosis (MS) and from a health care claims database. 
METHODS: This data source comparison was a secondary objective in a study utiliz-
ing both claims and linked medical chart data. Patients with MS were identiﬁed in a 
